your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Results of Roche trial NO 16966

Treatment group	FOLFOX + placebo	XELOX + placebo	FOLFOX + bevacizumab	XELOX + bevacizumab
N	351	350	349	350
	Both placebo groups		Both bevacizumab groups
PFS, median (months)	8.0		9.4 (p = .0023)
OS, median (months)	19.9		21.3
Response rate, percent	38 (49)*		38 (47)*

Results_Roche_trial_NO16966.htm

PFS: progression free survival; FOLFOX: oxaliplatin, 5FU, leucovorin; XELOX: capecitabine + oxaliplatin; OS: overall survival.
* Objective response rates according to independent review committee, followed by investigator-reported rates, in parentheses.

Data from: Saltz, LB, et al. J Clin Oncol 2008; 26:2013.

Graphic 72526 Version 1.0